Chikungunya virus (CHIKV) continues to be a public health challenge across Asia, Africa and Latin America. Yet, despite its widespread impact, reliable, sensitive and scalable diagnostics for Chikungunya remain limited,…
In the world of biosimilars, diagnostics, and regulated bioanalytics, an ELISA kit is only as useful as its validation. Yet many teams underestimate the complexity of taking a good-looking ELISA curve…
A CRO’s Guide to Smarter Scientific Scale-Up In today’s fast-paced biotech and diagnostics landscape, antibody development is not just a lab function — it is a strategic decision. For startups,…
India is rapidly emerging as a global player in biopharmaceutical innovation, diagnostics, and vaccine manufacturing. Yet, amid this growth lies a quiet but critical bottleneck: our dependency on imported biological reagents. From…
Chinese Hamster Ovary (CHO) cells are the backbone of modern biologics manufacturing, producing most therapeutic antibodies and recombinant proteins. During CHO-based production, host cell proteins (HCPs) – native CHO proteins – inevitably…
When you are developing a biosimilar, designing an assay, or characterizing a biologic, the antibody you use is not just a tool, it is the foundation of your data. While…
In the complex world of drug discovery, every interaction matters. Whether it is a small molecule binding to a receptor, or an antibody interacting with its antigen, understanding these interactions…
As India accelerates its leadership in biosimilar development, regulatory expectations are evolving rapidly. The Central Drugs Standard Control Organization (CDSCO) has updated its guidelines in 2025 to align with global agencies like…
Biosimilars are transforming the future of healthcare. With rising healthcare costs and increasing demand for affordable biologic therapies, biosimilars offer a powerful solution. But there's one major bottleneck to adoption…
The Central Drugs Standard Control Organization (CDSCO) has released its 2025 draft revision of the "Guidelines on Similar Biologics" for marketing authorization in India. This update brings India's biosimilar regulatory…
In the rapidly evolving landscape of biologics, biosimilars are taking center stage. As the global demand for affordable & effective therapeutic solutions rises, biosimilar development has become a focal point…
POV: you are a biotech innovator with a breakthrough biologic or diagnostic platform. Building your own R&D infrastructure from hires, labs and certifications can cost $2–5 million and take 18–24…
